Recent case reports published in Sexual medicine journal This paper details the experiences of two men who were relieved of a rare debilitating condition caused by ejaculation. Patients who suffered from severe flu-like cognitive symptoms after orgasm experienced significant improvement after taking antidepressants. These discoveries provide potential treatment options for diseases for which there are currently no standard treatments.
Post-orgasmic illness syndrome is a medical condition characterized by physical and cognitive symptoms that occur immediately after experiencing an orgasm. People with this condition often report extreme fatigue, muscle weakness, fever, and difficulty concentrating. These symptoms usually last between 2 and 7 days and often lead to avoidance of sex altogether.
The emotional burden of this condition can be severe. Men dealing with these symptoms often report low self-esteem, feelings of helplessness, and extreme tension in intimate relationships. Many patients believe that there is a fundamental flaw in their physical or psychological makeup and have internalized the belief that they are the cause of their sexual difficulties.
The exact biological mechanisms behind this disease are still poorly understood. Some medical professionals suspect this condition is due to an autoimmune reaction in which the body mistakenly attacks its own semen. Other researchers have proposed that the syndrome is caused by a nervous system and hormonal imbalance, particularly involving brain chemicals such as serotonin and dopamine.
Doctors are having a hard time finding reliable treatments because the root cause is still debated. Past attempts have included allergy drugs, anti-inflammatory drugs, and even treatments aimed at desensitizing the immune system to semen. However, these interventions often yield inconsistent results, leaving many patients unsaved.
Thalia Helder, a psychiatrist at Utrecht University Medical Center in the Netherlands, and her colleagues have written a new report to explore alternative treatment routes. They wanted to investigate whether modulating specific chemical signals in the brain could reduce physical and mental fatigue. The research team focused on the use of sertraline, a common drug known as a selective serotonin reuptake inhibitor.
This type of drug is typically prescribed for depression and anxiety, but it also changes the way the brain deals with stress responses and sexual function. By increasing the availability of serotonin between nerve cells, this drug may help stabilize the nervous system after the intense physical and emotional release of orgasm. Herder and her team documented the clinical outcomes of two patients who received this treatment.
The first patient was a 28-year-old man who had experienced extreme fatigue, general unwellness, nasal congestion, and post-orgasm “brain fog” throughout his life. These symptoms reliably appeared within an hour after ejaculation and lasted up to a week. The man had previously tried taking allergy medication and painkillers, but neither had any effect.
During his clinical evaluation, doctors noted that he became extremely irritable and struggled with mental clarity during post-orgasmic episodes. He also revealed a long history of severe discomfort in social situations, and his medical team diagnosed him with social anxiety disorder. To address both social anxiety and post-orgasm symptoms, his doctor prescribed daily doses of sertraline.
After 3 months of gradually increasing the dosage, the patient reported a significant reduction in both social anxiety and post-orgasmic symptoms. His physical fatigue and cognitive fog intensity decreased and the duration of his symptoms shortened. He did not experience any harmful side effects from the drug.
The second patient was a 29-year-old man who experienced deep fatigue, muscle pain, and a lingering sense of worthlessness after having sex with a partner and masturbating. These issues have plagued him since he first became sexually active as a teenager. His post-orgasmic symptoms routinely impaired his performance at work, forcing him to schedule his sexual activities around his work schedule.
This patient also had a lifelong problem with premature ejaculation, a condition that did not respond to exercise or numbing ointments. Selective serotonin reuptake inhibitors are known to delay ejaculation, so the doctor prescribed daily doses of sertraline. Within a month of starting the drug, my time to ejaculation increased significantly.
In addition to improved sexual function, men noticed a significant reduction in post-orgasm muscle pain, weakness, and mood disturbances. The researchers noted that this treatment effect remained stable over the three-year observation period. Like the first patient, he experienced no noticeable negative side effects from the daily medication.
Researchers suggest that sertraline may work by calming the body’s neuroendocrine system. Orgasm involves a coordinated burst of autonomic and endocrine activity, including the release of various hormones and stress signals. In people with post-orgasmic illness syndrome, this system can become dysregulated, leading to a prolonged and exhausting stress response.
Sertraline helps calm excessive stress-related signaling in the brain by blocking serotonin reuptake. This drug also has a small effect on dopamine, a chemical associated with motivation and reward. Normalizing these pathways can prevent the severe drop in energy and mood that characterizes the post-ejaculatory crash.
Although these results are very promising, the researchers caution that a definitive cause-and-effect relationship cannot be established from just two patients. Case reports are observational reports of individual treatments, meaning they lack the rigorous controls found in large clinical trials. The statistical strength of these results was not significant because the sample size was too small to draw broad mathematical conclusions.
The drug may only work for certain people. Patients whose symptoms are caused by nervous system imbalance or underlying anxiety may respond well, whereas patients with primary immune system allergies may not respond. Other limitations include the lack of standardized symptom tracking and the presence of overlapping psychiatric disorders in both men.
Despite these shortcomings, case reports represent an important starting point for medical discovery. This allows physicians to share new observations and unexpected treatment successes that may otherwise go undocumented. By publishing these individual successes, researchers can generate new hypotheses and guide the design of larger, more rigorous studies.
The authors recommend that scientists conduct controlled clinical trials in the future to better understand how selective serotonin reuptake inhibitors interact with this particular syndrome. Future research should aim to identify precise biological markers that predict whether a patient will respond to these types of drugs. Until then, the findings suggest that doctors should consider assessing a patient’s psychological and neurological profile when seeking individualized treatments.
The study, “Postorgasmic Illness Syndrome (POIS) in Two Patients Responding to Sertraline: A Case Report,” was authored by Thalia Herder, Rikus Knegtering, Nynke Boonstra, and Kor Spoelstra.
